SUSVIMO is a small eye implant placed during a short (~30-minute), one-time, outpatient procedure.
If your retina specialist determines that it is necessary, you may need an anti-VEGF injection in the gel-like part of the SUSVIMO-treated eye (intravitreal) before your next refill.
†In clinical trials for DME, people maintained vision similar to monthly ranibizumab injections over 1 year. There was a temporary drop in vision after the SUSVIMO procedure.
Yes. Treatment with SUSVIMO requires an implant to be placed in the affected eye during a one-time, outpatient procedure. After that, your retina specialist may schedule follow-up visits to make sure your eye has healed properly.
There is more to know about the implant procedure and medication refills, please see the What to expect with SUSVIMO page for more information and procedure guidance.
SUSVIMO may be right for you if:
Ask your retina specialist what twice-yearly SUSVIMO could mean for you.*
If your retina specialist determines that it is necessary, you may need an anti-VEGF injection in the gel-like part of the SUSVIMO-treated eye (intravitreal) before your next refill.
After receiving your SUSVIMO implant, your eye will need time to heal. Once it heals, you shouldn’t notice the implant or experience any pain or discomfort. The SUSVIMO implant is located underneath your eyelid and is not visible to others.
SUSVIMO is refilled twice-yearly (approximately every 6 months) in your retina specialist’s office.* The new medicine is injected directly into the implant so you can have continuous treatment 24/7 for 6 months.*
If your retina specialist determines that it is necessary, you may need an anti-VEGF injection in the gel-like part of the SUSVIMO-treated eye (intravitreal) before your next refill.
If you miss a scheduled refill, call your retina specialist as soon as possible to reschedule. Keeping your schedule is important—it’s the best way to ensure your retina specialist can monitor your vision.
The most common side effects of SUSVIMO:
These are not all the possible side effects of SUSVIMO. If necessary, SUSVIMO can be removed in an outpatient procedure.
The most serious side effects of SUSVIMO are:
If you experience any side effects, notify your retina specialist immediately.
When someone finds out they have DME, they may be overwhelmed about their treatment. You can play an important part in helping manage their vision challenges and easing their concerns. The best ways to help are ensuring they adhere to post-procedure guidance and keep up with their treatment schedule. In addition, educate yourself about SUSVIMO and what to do in case of side effects.
Get help understanding your insurance coverage and assistance options from Genentech Ophthalmology Access Solutions. Genentech Ophthalmology Access Solutions can help you learn if your health insurance covers SUSVIMO treatment and refer you to appropriate financial assistance options if you are eligible.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.